Cointime

KAHR medical

company

About

KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.

  • 1 - 10

Highlights

Total Funding Amount
$67.50M
Funding Rounds
3
Investors
2

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$3M
Industries
Biotechnology,Medical,Pharmaceutical
Founded date
Jan 1, 2005
Number Of Employee
1 - 10
Operating Status
Active

KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$67.50M
KAHR medical has raised a total of $67.50M in funding over 2 rounds. Their latest funding was raised on Jun 16, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 16, 2021 Series Unknown $46.50M 1 — — Detail
Feb 25, 2020 Series Unknown $18M 1 — — Detail
Apr 14, 2011 Series Unknown $3M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
KAHR medical is funded by 2 investors. Pavilion Capital and Sanofi are the most recent investors.
Investor Name Lead Investor Funding Round
Pavilion Capital — Series Unknown
Sanofi — Series Unknown
Cointime
Chủ Đề
Công Ty